---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-151808"
form_type: "8-K"
ticker: null
cik: "0001492674"
company_name: "T2 Biosystems, Inc."
filed_at: "2023-05-23T23:59:59+00:00"
generated_at: "2026-06-14T17:16:07.303270+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# T2 Biosystems receives Nasdaq delisting notice for market value below $35M

## Summary
- MVLS below $35M minimum for 30 consecutive business days as of Nov 22, 2022; compliance period ended May 22, 2023.
- Nasdaq notified T2 on May 23, 2023 that shares fail to comply and are subject to delisting.
- Company will appeal and request a hearing to stay delisting pending Panel decision.
- T2 intends to present a plan to regain compliance, but no assurance of success.

## SEC filing metadata
- accession: 0001193125-23-151808
- form_type: 8-K
- cik: 0001492674
- company_name: T2 Biosystems, Inc.
- filed_at: 2023-05-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492674/000119312523151808/0001193125-23-151808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492674/000119312523151808/d447004d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-151808
- JSON: https://secwatch.observer/filing/0001193125-23-151808.json
- Plain text: https://secwatch.observer/filing/0001193125-23-151808.txt

## Key facts
- Listing & Compliance Notices
  T2 Biosystems, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: May 23, 2023 we received a letter from Nasdaq informing us that our shares have failed to comply with the MVLS required for continued listing on The Nasdaq Capital Market and, as a result, our shares are subject to delisting. We will file an appeal and hearing request with Nasdaq, which will stay the delisting of our common stock from The Nasdaq Capital Market pending a Nasdaq listing qualifications hearings panel’s (the “Panel”) decision. There can be no assurance that the Panel will grant our request for continued listing; however, we intend to present a plan to regain compliance to the Pane
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312523151808/0001193125-23-151808-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.